Epidemiology of Interstitial Cystitis: 2

Held, Philip J.; Hanno, Philip M.; Wein, Alan J.; Pauly, Mark V.; Cahn, Marjorie A.

doi:10.1007/978-1-4471-3293-6_4

Cited by 144 publications

(99 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Held and colleagues reported that 30% to 46% of BPS patients can go into remission for an average of 8 months. 20 This symptom fluctuation is important in reporting the long-term efficacy of PPS.…”

mentioning

confidence: 99%

Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome

Al-Zahrani¹,

Gajewski²

2013

CUAJ

View full text Add to dashboard Cite

Objective: The primary objective of this study is to report on thelong-term efficacy and tolerability of pentosan polysulphate sodium(PPS) in patients with bladder pain syndrome (BPS). The secondaryobjective is to find the predictors of the long-term outcome.Methods: This is a single institution, retrospective study. The studyperiod was from 1994 to 2008. All patients fulfilled the clinicalcriteria of BPS, as suggested by European Society for the Study ofInterstitial Cystitis. We included only patients with de novo BPSdiagnosis and no previous PPS or other treatment. The efficacyof PPS was measured with the global response assessment scale(GRA). Patients were stratified into 2 groups based on the durationof the treatment. Group 1 took the drug for less than 12 months.Group 2 took the drug for more than 12 months.Results: There were 271 patients eligible for the study. Most of thepatients were female (90%), with the mean age at presentation of45.5 years. The average duration of symptoms was 28.5 months.The mean follow-up was 22 months (range 3-130). Out of all thepatients, 147 patients (54.2%) reported over 50% improvementusing the GRA. The reported efficacy was higher in Group 2 (60%).Ninety-three patients (34.3%) decided to stop taking the medicationfor various reasons. The most common reasons to stop themedication were poor outcome (16.6% of patients) and side effects(11.1% of patients). Poor outcome was associated with nocturia,smoking and detrusor overactivity. Good outcome was associatedwith longer PPS intake (>12 months) and severe cystoscopic findingsof glomerulation.Conclusion: Pentosan polysulphate sodium is an effective oraltherapy to control the symptoms of BPS with good long-term efficacyand tolerability.

show abstract

mentioning

confidence: 99%

Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome

Al-Zahrani¹,

Gajewski²

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Previous investigators reported 57 -73% of IC/PBS patients gained relief of pain with urination (15,21) . Of our patients, 67 (49%) reported this symptom.…”

Section: Discussionmentioning

confidence: 98%

Using the International Continence Society’s definition of painful bladder syndrome

Warren

Meyer

Greenberg

et al. 2006

Urology

View full text Add to dashboard Cite

Objectives-The case definition of interstitial cystitis (IC) is in flux. The International Continence Society (ICS) suggested a definition for the painful bladder syndrome (PBS), a concept embraced by many IC investigators, some of whom have used the name IC/PBS. In a study of recent onset IC/ PBS patients, we had two objectives: to determine 1) what proportion met the ICS definition and 2) how did those who met the definition differ from those who did not.Methods-Having recruited women who had recent onset IC/PBS for an ongoing case control study to identify its risk factors, we studied our first 138 eligible cases to identify those who met the ICS definition. We then compared those who met the definition to those who did not by variables acquired through interviews and medical records. The most liberal interpretation of the ICS definition did not include 47/138 (34%) of our cases. Comparing these to the 91 (66%) who did meet the ICS criteria, we found that 96/97 clinical variables, including many generally thought characteristic of IC/PBS, were not significantly different between the 2 groups. Results-The

show abstract

“…Patients were assessed for eligibility in the clinic within 14 days before the scheduled start of study treatment. On day 1, eligible patients were randomly allocated on a 1:1 basis to receive (double-blind) either PSD597 (a patented combination of 200 mg lidocaine, alkalinized with a sequential instillation of 8.4% sodium bicarbonate solution, to a final volume of 10 mL) or placebo (10 mL of ordinary saline), instilled into an empty bladder once a day for 5 consecutive days (days [1][2][3][4][5] Primary efficacy was assessed at 15 days using a 7-point Global Response Assessment (GRA). For the GRA the patient was asked 'As compared to when you started the current study, how would you rate your overall bladder symptoms now?'…”

Section: Methodsmentioning

confidence: 99%

“…The estimated ratio of women to men is 1:10 to 1:5 [1]. IC severely affects quality of life, being described as worse than end-stage renal disease [2]. The relief of symptoms and disease remission are the primary goals of any treatment plan.…”

Section: Introductionmentioning

confidence: 99%

Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome

et al. 2009

View full text Add to dashboard Cite

OBJECTIVE To assess the immediate and sustained relief of the symptoms of interstitial cystitis/painful bladder syndrome (IC/PBlS) after a consecutive 5‐day course of treatment with intravesical alkalinized lidocaine (PSD597), and to characterize the pharmacokinetics of single and multiple doses of intravesical PSD597 in a subgroup of patients. PATIENTS AND METHODS In all, 102 adult patients (99 women) with a clinical diagnosis of IC/PBlS were randomized from 19 centres in the USA and Canada to receive a daily intravesical instillation of PSD597 (200 mg lidocaine, alkalinized with a sequential instillation of 8.4% sodium bicarbonate solution, to a final volume of 10 mL) or placebo (double‐blind), for 5 consecutive days. Patients were followed at intervals up to 29 days after the first instillation. Efficacy was assessed by changes in the Global Response Assessment (GRA), Likert scales for bladder pain, urgency and frequency, and validated O’Leary‐Sant IC symptom and problem indices. RESULTS Significantly more patients treated with PSD597 rated their overall bladder symptoms as moderately or markedly improved on the GRA scale 3 days after completing the 5‐day course of treatment (30% and 9.6%, respectively, for patients treated with PSD597 and placebo; P = 0.012). The treatment effects were also maintained beyond the end of treatment and are further supported by the secondary endpoints, including symptom and problem indices. The peak serum lidocaine concentration during the study was <2 µg/mL, and well below the toxic level (>5 µg/mL). CONCLUSION This preliminary study showed that PSD597 was effective for providing sustained amelioration of symptoms of IC/PBlS beyond the acute treatment phase. The drug was safe, well tolerated and devoid of the systemic side‐effects often experienced with oral drug administration. Long‐term studies are needed to determine the optimum regimen to maintain this favourable treatment effect.

show abstract

Epidemiology of Interstitial Cystitis: 2

Cited by 144 publications

References 18 publications

Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome

Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome

Using the International Continence Society’s definition of painful bladder syndrome

Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome

Contact Info

Product

Resources

About